AbbVie is all set to install its first manufacturing facility in Asia which will be operational from 2019. Located in Singapore, this facility will support an emerging antibody-drug conjugate (ADC) pipeline. This would be the first facility of AbbVie since it had split out of Abbott Laboratories in 2012 and made its own identity.
The facility will be housing the ADC platform technologies of the company. It will be home to immunology and oncology pipelines. At the new unit, biologic and potent small molecules would be manufactures under one roof. Hence, it would enable the creation of potent drugs, which have targeted approach in drug delivery. Furthermore, with both large and small molecules being available at the same site, it would help create synergies between analytical testing and support structure. Through the plant almost 250 additional jobs would be created in Singapore, where it presently employs 120 people. The outputs of the facility would be supplied world over.
The overall investment for the project would be approximately around 432 million Euros (US$ 320 million).